"Our business strategy, which is focused on building a strong portfolio of oncology products and a growing base of global customers, continues to drive record performance." said Dr. Jo Shen, President and CEO of ScinoPharm.

Active pharmaceutical ingredient (API) specialist ScinoPharm reported a 43% rise in its annual revenue to US$44.9 million for 2006, and a positive net income for the first year since the company’s inception.